COLLCOLLEGIUM PHARMACEUTICAL, INC同业对比
COLLEGIUM PHARMACEUTICAL, INC 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COLL本股 | $723M#7 | 17.5x#3 | 2.3x#3 | 0.9x#1 | 23.6%#5 | -8.7%#9 | 23.0%#2 | 20.2%#3 | 62.0%#1 | 4#1 | -37.7%#10 | — |
| GERN | $832M#1 | — | 3.8x#6 | 3510.6x#8 | -60.2%#8 | 52.2%#4 | -28938.8%#8 | -38.2%#10 | -24.8%#5 | — | — | — |
| RIGL | $831M#2 | 2.6x#1 | 2.0x#2 | 2.8x#2 | 64.1%#4 | 1999.1%#1 | 42.6%#1 | 86.3%#1 | 30.6%#2 | — | 27.0%#7 | — |
| CLYM | $810M#3 | — | 3.4x#5 | — | — | 19.0%#6 | — | -25.0%#8 | — | — | 600.2%#1 | — |
| ACRS | $784M#4 | — | 6.3x#10 | 100.2x#7 | -58.2%#7 | 50.8%#5 | -975.9%#6 | -52.1%#11 | -65.8%#6 | 3#2 | 190.2%#3 | — |
| DSGN | $783M#5 | — | 3.9x#7 | — | — | -40.7%#11 | — | -34.6%#9 | — | — | 114.3%#4 | — |
| GYRE | $749M#6 | — | 6.9x#11 | 6.4x#3 | 10.2%#6 | -44.8%#12 | 9.9%#3 | 9.2%#4 | 12.0%#3 | 3#2 | — | 6.0%#1 |
| NVCT | $712M#8 | — | 78.4x#13 | — | — | -39.2%#10 | — | -291.1%#12 | — | — | 252.4%#2 | — |
| ZVRA | $701M#9 | 12.7x#2 | 3.2x#4 | 6.6x#4 | 350.9%#1 | 178.9%#3 | -59.1%#4 | 38.2%#2 | — | — | — | — |
| MNPR | $679M#10 | — | 5.2x#9 | — | — | 12.0%#7 | — | -10.5%#6 | — | — | 77.8%#5 | — |
| VSTM | $665M#11 | — | 13.3x#12 | 21.5x#5 | 209.1%#2 | -60.3%#13 | -550.3%#5 | -419.1%#13 | — | — | -19.5%#9 | — |
| CBIO | $637M#12 | — | 3.9x#8 | 58.7x#6 | — | 306.4%#2 | -1407.5%#7 | 0.1%#5 | — | — | 37.1%#6 | — |
| ALT | $632M#13 | — | 1.3x#1 | 15419.1x#9 | 105.0%#3 | 7.3%#8 | -230461.0%#9 | -18.6%#7 | -21.1%#4 | — | -10.7%#8 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议